Financials
Financial year 2025
LINEA TROVATA BIOPROJECTS from Lokeren, company number BE0894233694, closed financial year 2025 with a result of € 168,627 after tax. For that financial year LINEA TROVATA BIOPROJECTS recorded a gross margin of € 182,881 and equity of € 985,193. Compared with financial year 2024, the result moved from € 278,826 to € 168,627. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 985,193
▲ 21% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 168,627
▼ 40% vs 2024
Profit after tax over the fiscal year.
€ 26,777
▲ 7% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 737,193.
Debts at end 2025
€ 150,000
▼ 64% vs 2024
Loans from banks and other lenders, long and short.
€ 43,705
▲ € 37,366 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 40,092
▲ € 36,046 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -4,998 | € 134,715 | € 293,799 | € 182,881 | ▼ 38% |
| Profit after taxes | € 126,679 | € 278,604 | € 278,826 | € 168,627 | ▼ 40% |
| Equity | € 259,136 | € 537,740 | € 816,566 | € 985,193 | ▲ 21% |
| Total debts | € 800,882 | € 659,910 | € 496,265 | € 280,907 | ▼ 43% |
| Cash | € 48,521 | € 18,249 | € 25,108 | € 26,777 | ▲ 7% |
| Retained profit | € 11,136 | € 289,740 | € 568,566 | € 737,193 | ▲ 30% |
| Bank debt | € 685,000 | € 545,000 | € 415,000 | € 150,000 | ▼ 64% |
| Balance sheet total | € 1,060,018 | € 1,197,650 | € 1,312,831 | € 1,266,101 | ▼ 4% |
Key figures of LINEA TROVATA BIOPROJECTS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LINEA TROVATA BIOPROJECTS?
What happened at LINEA TROVATA BIOPROJECTS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Bio&nergy stepped down as director. NBB
- Robin Van Poucke stepped down as director. NBB
- Marijke Steendam stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 168,627 (▼ 40% vs 2024). Source: NBB ↗
- Bio&nergy became a director. NBB
- Robin Van Poucke became a director. NBB
- Marijke Steendam became a director. NBB
- New establishment in Lokeren. KBO
In short
From € 126,679 profit in 2022 to € 168,627 profit in 2025.
Best year ever: 2024, with € 278,826 profit.
A new publication or filing at LINEA TROVATA BIOPROJECTS? We notify you, reason included.
Follow LINEA TROVATA BIOPROJECTSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Bio&nergy comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
LINEA TROVATA BIOPROJECTSThe shares are held by Bio&nergy (78.3%). It owns 40% of Aesco and 40% of Sun Invest itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Piet Van Poucke
Also active at: Building Solar Invest, AESCO
since 2023 · until 2029
Robin Van Poucke
Director
since 2023 · until 2029
since 2023 · until 2029
Shareholders
78.3%
Participations
40%
40%
Establishments
Establishment units
Physical locations of this company
Zamanstraat 37
9160 Lokeren
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 9 companies are registered at this address.
All companies at this address →SUN INVEST same network
€ 836,814 gross margin · 2025
JULIS ENERGIES
€ 68,810 gross margin · 2025
MAGMA ENERGIES
€ 469,801 gross margin · 2025
VAN MAELE ENERGIES
€ 55,372 gross margin · 2025
ENSOL SUN INVEST
€ 129,201 gross margin · 2025
+4 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0894.233.694
- VAT number
- BE 0894.233.694
- Registered office
- Zamanstraat 37, 9160 Lokeren
- Names & denominations
- LINEA TROVATA BIOPROJECTS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 17 December 2007
- Peppol
- Active · Active since 23 Nov 2025
- Activities · NACE
Activiteiten van hoofdkantoren
Bouw van andere civieltechnische werken, neg